TheraRadar
← Back
Data updated: Jun 28, 2026

MEDRX USA

Pharma
Pharmaceuticals Execution: Excellent

MEDRX USA is a pharmaceutical company with 1 FDA-approved products.

2025
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

MEDRX USA at a Glance

  • Strong track record with 100% execution quality across 5 trials
  • Fast trial execution (10 months median completion)

MEDRX USA's Key Drugs

MEDRX USA's core commercial portfolio centers on BONDLIDO — its most strategically important drugs approved in the last 15 years.

BONDLIDO
Pain

Post-Herpetic Neuralgia

Approved 2025

MEDRX USA's Recent FDA Approvals

MEDRX USA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BONDLIDO NDA
2025-09-24
lidocaine
Post-Herpetic Neuralgia

MEDRX USA's Therapeutic Areas

Disease areas where MEDRX USA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

MEDRX USA Pipeline Snapshot

Active clinical trials for MEDRX USA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • BONDLIDO leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 5/5 completed
  • • Speed: 10 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges